Semaglutide vs tirzepatide: what the trial data actually shows

What's this video probably claiming?

Based on the caption and creator context, @nursesharai is likely walking viewers through the basic pharmacology of semaglutide and tirzepatide, explaining that tirzepatide works on two receptor pathways (GIP and GLP-1) while semaglutide targets only GLP-1. The video probably frames tirzepatide as the more effective option for weight loss, possibly citing head-to-head comparisons or superior percentage body weight reduction. Nurse creators on TikTok tend to present these comparisons confidently, which is fine when the data supports it, but the framing often skips over who actually benefits more from each drug, whether insurance or access factors matter, and what the dropout rates in trials looked like. The dual-agonist angle gets simplified into a 'two is better than one' narrative that sounds clean but obscures a more complicated clinical picture.

What does the science actually show?

The trial data is genuinely impressive for both drugs, but tirzepatide does edge ahead on weight outcomes at equivalent treatment durations. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean body weight reduction of approximately 20.9% over 72 weeks in adults with obesity. STEP 1 (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg achieved roughly 14.9% mean body weight reduction over 68 weeks. That is a real difference, not a rounding error. The SURMOUNT-5 trial, which ran a more direct head-to-head comparison, found tirzepatide outperformed semaglutide on weight reduction endpoints. However, both drugs carry similar GI side effect profiles, and neither trial was designed to tell you which drug is right for a specific patient. Cardiovascular outcome data for semaglutide (SELECT trial, Lincoff et al., 2023, NEJM) is more mature than tirzepatide's, which matters clinically.

Where does the social media noise diverge from clinical reality?

The biggest distortion on TikTok around these two drugs is the implied universality of the comparison. Tirzepatide showing stronger average weight loss in trials does not mean every patient loses more weight on tirzepatide. Individual response varies substantially, and some patients plateau on tirzepatide while responding well to semaglutide. The 'dual pathway equals better' framing also glosses over the fact that GIP receptor agonism is still not fully understood mechanistically. Researchers are not entirely certain how much of tirzepatide's extra efficacy comes from GIP activation versus its specific GLP-1 receptor binding characteristics. Finan et al. and other preclinical researchers have noted that GIP's role in human energy metabolism is more complex than early models suggested. Social media also almost never mentions that compounded versions of these drugs, which many patients access, are not bioequivalent to the FDA-approved branded formulations and carry different risk profiles.

What should you actually know?

If you are trying to decide between these medications with a clinician, the honest answer is that tirzepatide has stronger average weight loss data and semaglutide has stronger cardiovascular outcome data, at least for now. Both require weekly injections, both cause nausea and GI discomfort especially during dose escalation, and both lose effectiveness if discontinued without lifestyle support. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed weight regain after semaglutide discontinuation, and similar patterns are expected with tirzepatide. These are chronic medications, not courses of treatment. Neither drug is a cure for obesity. Compounded semaglutide and compounded tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro, a distinction that matters for safety and efficacy expectations. Any video that does not mention that distinction is leaving out something important.